Trial · NCT07882472
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with adverse events | Up to seven days | Absolute values and change from baseline |
| Primary | Number of participants with abnormal lab test results | Up to seven days | Absolute values and change from baseline for clinical chemistry and hematology |
| Primary | Number of participants with abnormal vital signs | Up to seven days | Absolute values and change from baseline (oral body temperature, respiratory rate, blood pressure, and heart rate) |
| Primary | Number of participants with abnormal ECG | Up to seven days | Absolute values and change from baseline ECG intervals |
| Secondary | Pharmacokinetic Cmax | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Maximum (peak) observed concentration of DTI-117 |
| Secondary | Pharmacokinetic Tmax | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Time to maximum observed concentrations of DTI-117 |
| Secondary | Pharmacokinetic half-life (t1/2) | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Time to terminal elimination half-life concentrations of DTI-117 |
| Secondary | Pharmacokinetic AUClast | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Area under the concentration-time curve from zero to the last concentration quantifiable for DTI-117 |
| Secondary | Pharmacokinetic AUCinf | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Area under the plasma concentration-time curve from time zero extrapolated to infinity for TI-117 |
| Secondary | Pharmacokinetic CL/F | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Apparent total plasma clearance after oral administration of TI-117 |
| Secondary | Pharmacokinetic VzF | Pre-dose and at 1, 2, 5, 10, 20, 40, and 60 minutes and 2 and 6 hours post-dose | Apparent volume of distribution during terminal elimination phase after oral administration of DTI-117 |
| Secondary | Time to urination and defecation | 24 hours post-dose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07882472/registered